LMR Partners’s ADMA Biologics ADMA Stock Holding History

LMR Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-42,622	Closed	-$68K	–	977
2021 Q2	$68K	Buy	+42,622	New	+$75K	﹤0.01%	939

Other funds holding ADMA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's ADMA Position: Q3 2021 in Review

LMR Partners sold out of ADMA Biologics (ADMA) in Q3 2021, closing a stake of 42,622 shares — an estimated $68K sold.

LMR Partners first reported a position in ADMA in Q2 2021 and held it in 1 quarter. The position peaked at $68K in Q2 2021. 72 funds tracked by Wall St. Rank hold ADMA as of Q3 2021.

LMR Partners reported no remaining ADMA Biologics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 42,622 ADMA Biologics shares in Q3 2021, an estimated $68K.
LMR Partners first reported a position in ADMA Biologics in Q2 2021 and held it in 1 quarter.
LMR Partners's ADMA Biologics position peaked at $68K in Q2 2021.
72 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.